Abstract
Background
In the nonambulatory cerebral palsy (CP) population with a prior history of fracture, the use of pamidronate is not always effective in preventing further fractures.
Objective
To test the hypothesis that when fractures occur after cyclic pamidronate, they will be at the proximal or distal end of a pamidronate band.
Materials and methods
Retrospective review of our CP patient database revealed 53 children who had received one or more complete courses of pamidronate therapy (five cycles over 12 months). Medical records were screened to identify children who had sustained a fracture or fractures after completing treatment.
Results
Of 53 patients treated with pamidronate, only 14 sustained fractures after treatment. Radiographs were available for 11 patients, showing 19 fractures. Sixty-three percent of these fractures were located at a junction with pamidronate bands but not within the bands.
Conclusions
We propose stress risers as the mechanism for fractures that have occurred where bone mineral density abruptly changes as a result of cyclic administration of pamidronate. We show a theoretical example of how alternative dosing might reduce the ratio and therefore decrease the chance of formation of a stress riser.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Bachrach SJ, Kecskemethy HH, Harcke HT et al (2010) Decreased fracture incidence after 1 year of pamidronate treatment in children with spastic quadriplegic cerebral palsy. Dev Med Child Neurol 52:837–842
Plotkin H, Bruzoni M, Coughlin S et al (2006) Low doses of pamidronate for the treatment of osteopenia in children with cerebral palsy. Dev Med Child Neurol 48:709–712
Bachrach SJ, Kecskemethy HH, Harcke HT et al (2006) Pamidronate treatment and post treatment bone density in children with spastic quadriplegic cerebral palsy. J Clin Densitom 9:167–174
Henderson RC, Lark RK, Kecskemethy HH et al (2002) Bisphosphonates to treat osteopenia in children with quadriplegic cerebral palsy: a randomized, placebo-controlled clinical trial. J Pediatr 141:644–651
Shaw NJ, White CP, Fraser WD et al (1994) Osteopenia in cerebral palsy. Arch Dis Child 71:235–238
Rauch F, Munns C, Land C et al (2006) Pamidronate in children and adolescents with osteogenesis imperfecta: effect of treatment discontinuation. J Clin Endocrinol Metab 91:1268–1274
Marx RE, Sawatari Y, Fortin M et al (2005) Bisphosphonate-induced exposed bone (osteonecrosis/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment. J Oral Maxillofac Surg 63:1567–1575
Whyte MP, Wenkert D, Clements KL et al (2003) Bisphosphonate-induced osteopetrosis. N Engl J Med 349:457–463
Grissom LE, Harcke HT (2003) Radiographic features of bisphosphonate therapy in pediatric patients. Pediatr Radiol 33:226–229
Staheli L (2006) Practice of pediatric orthopedics, 2nd ed. Lipincott, Williams, and Wilkins, Philadelphia p 267
Alford JW, Bradley MP, Fadale PD et al (2007) Resorbable fillers reduce stress risers from empty screw holes. J Trauma 63:647–654
Miller F, Dabney KW, Rang M et al (1995) Complications in cerebral palsy treatment. In: Epps CH Jr, Bowen JR (eds) Complications in pediatric orthopaedic surgery. Lippincott, Philadelphia
Hernandez CJ (2008) How can bone turnover modify bone strength independent of bone mass? Bone 42:1014–1020
Andiran N, Alikasifoglu A, Gone N et al (2008) Cyclic pamidronate therapy in children with osteogenesis imperfecta: results of treatment and follow-up after discontinuation. J Pediatr Endocrinol Metab 21:63–72
Henderson RC, Lark RK, Newman JE et al (2002) Pediatric reference data for dual x-ray absorptiometric measures of bone density in the distal femur. AJR 178:439–443
Zemel BS, Stallings VA, Leonard MB et al (2009) Revised pediatric reference data for the lateral distal femur measured by dual energy x-ray absorptiometry. J Clin Densitom 12:207–218
Aspenberg P (2009) Bisphosphonates and fatigue fractures. IBMS BoneKEy 6:465–467
Neviaser AS, Lane JM, Lenart BA et al (2008) Low-energy femoral shaft fractures associated with alendronate use. J Orthop Trauma 22:346–350
Ing-Lorenzini K, Desmeules J, Plachta O et al (2009) Low-energy femoral fractures associated with the long-term use of bisphosphonates. Drug Saf 32:775–785
Bishop NE, Ferguson S, Tepic S (1996) Porosity reduction in bone cement at the cement-stem interface. J Bone Joint Surg 78B:349–356
Rauch F, Cornibert S, Cheung M et al (2007) Long-bone changes after pamidronate discontinuation in children and adolescents with osteogenesis imperfecta. Bone 40:821–827
Harcke HT, Taylor A, Bachrach S et al (1998) Lateral femoral scan: an alternative method for assessing bone mineral density in children with cerebral palsy. Pediatr Radiol 28:241–246
Ward KA, Adams JE, Freemont TJ et al (2007) Can bisphosphonate treatment be stopped in a growing child with skeletal fragility? Osteoporos Int 18:1137–1140
Gandrud LM, Cheung JC, Daniels MW et al (2003) Low-dose intravenous pamidronate reduces fractures in childhood osteoporosis. J Pediatr Endocrinol Metabol 16:887–892
Steelman J, Zeitler P (2003) Treatment of symptomatic pediatric osteoporosis with cyclic single-day intravenous pamidronate infusions. J Pediatr 142:417–423
Acknowledgement
This work was presented at the Society for Pediatric Radiology meeting in Boston, MA, April 13–17, 2010.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Harcke, H.T., Stevenson, K.L., Kecskemethy, H.H. et al. Fracture after bisphosphonate treatment in children with cerebral palsy: the role of stress risers. Pediatr Radiol 42, 76–81 (2012). https://doi.org/10.1007/s00247-011-2198-9
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00247-011-2198-9